Digital visual of lungs showing cancer sites relevant to ADC lung cancer trials

RESEARCH

19 Jan 2026

Pfizer Moves Deeper Into ADCs With Pivotal Lung Cancer Trials

Pfizer advances an investigational ADC into Phase III lung cancer trials, testing monotherapy and combination approaches amid rising compe...

Aktis Oncology signage at Nasdaq symbolising biotech partnership and IPO plans

PARTNERSHIPS

14 Jan 2026

In Precision Oncology, Smart Alliances Are Beating Big Buys

Lilly’s stake in Aktis’s planned IPO shows how oncology partnerships are reshaping innovation by blending science, capital, and caution

FDA signage with vial representing orphan drug incentives in oncology regulation

REGULATORY

8 Jan 2026

Orphan Drug Incentives Shape Next Wave of Cancer Deals

US orphan drug incentives are quietly steering ADC development and deal-making, nudging firms toward rare cancers as precision oncology ac...

Graphic representation of antibody drug conjugates used in targeted cancer drug development

INVESTMENT

14 Nov 2025

A Small Deal With a Big Message for US Cancer Drugmakers

Day One’s Mersana buy shows how US drugmakers are moving earlier to lock up promising antibody-drug conjugates

Digital illustration of cancer cells analysed using AI for ADC precision oncology

TECHNOLOGY

5 Nov 2025

AI May Be the Missing Link in ADC Cancer Precision

AI-guided tissue analysis is sharpening patient selection, cutting trial risk, and speeding more precise ADC cancer drug development

Antibody drug conjugate molecules supporting next-generation cancer therapy development

PARTNERSHIPS

23 Oct 2025

Faster or Failed? ADC Developers Rethink How Drugs Get Built

Invenra and Xcellon Biologics link discovery and manufacturing early to speed next-generation ADCs toward the clinic

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.